PubMed Health⌕ Search

Biomedical subjects

M Diestelhorst

Publications and source records attributed to M Diestelhorst.

At least 37 records · Page 2Linked to original sources

Dry Drops: a new preservative-free drug delivery system.

PURPOSE: We compared the tolerability and safety of a lyophilisate (Dry Drops) with conventional eye drops containing the same polymer and electrolytes. In Dry Drops the active ingredient is incorporated in a drop of hydrophilic polymer solution freeze-dried on the tip of a soft hydrophobic carrier strip. Upon contact with tear film and/or conjunctiva the lyophilisate immediately rehydrates and detaches from the carrier. METHODS: Dry Drops containing HPMC as active ingredient and a preservative-free tear film substitute were applied to 64 eyes of 32 healthy volunteers according to a 22 factorial design in an open-label, cross-over, randomised study. Tolerability and safety were quantified and qualified at 0.5, 2, 5 and 10 min after administration via slit-lamp biomicroscopy, questionnaire and visual analogue scales. RESULTS: The differences between Dry Drops and conventional eye drops were not statistically significant. The initial sensation of Dry Drops was slightly less uncomfortable than that of the conventional ophthalmic solution. None of the eyes showed any clinical findings with safety implications. CONCLUSION: The safety and tolerability of a new application form were demonstrated in this phase I study. The improved chemical stability, exact dosing, reduced risk of lesions to the eye surface and good tolerability suggest that the new application device has promise for treatment in ophthalmology as well as in other medical subspecialties.

Adult↗

Morphologic proof of the toxicity of mitomycin C on the ciliary body in relation to different application methods.

BACKGROUND: Since postoperative hypotony has been a frequent complication of glaucomatous filtration surgery with adjunctive use of mitomycin C (MMC), the question arises of whether there may be another application method which can minimize this side effect. The purpose of this study was to establish the morphologic side effects of different application methods. METHODS: MMC 0.2 mg/ml was applied to the episclera of nine eyes of six pigmental rabbits at random via collagen shield (CS), soft contact lens (CL), or lyophilisate (20 microg; LY) for 5 min. Two eyes (controls) had a subconjunctival injection of BSS only. Another control eye was left untreated (no injection). No trabeculectomy was performed. One hour later the amounts of MMC in the conjunctiva and aqueous were analyzed by reverse-phase high-pressure liquid chromatography. Ciliary bodies were dissected from the enucleated eyes, embedded and investigated by transmission electron microscopy (TEM). Cell height of the nonpigmented ciliary epithelium was morphometrically assessed by means of computer-assisted image analysis. RESULTS: The light-microscopic analysis of the sectioned cell area revealed reduction of the cell height of the non-pigmented ciliary epithelium (NPCE) after application with soft contact lens (fourfold) and collagen shield (2.5-fold) but not with lyophilisate compared to the untreated eye. The following ultrastructural changes were seen: loss of apical microvilli (CS, CL, LY), disintegrating melanin granules within NPCE (CS), lysis of entire areas with NPCE cells (CS), myelin figures within mitochondria (LY), intracellular vacuoles (CS, CL), lysis of myelinated nerves (CS), myelin figures in mitochondria of endothelial cells (LY), and lysis of stromal fibrocytes (CS). In the control eyes (injection of BSS) none of these ultrastructural changes were detected in the cylindrical NPCE cells. The concentration of mitomycin in the aqueous humor after topical application of MMC on the episclera for 5 min were all below the detection limit (<10 ng/ml). The concentration of MMC in the conjunctiva ranged from 2.1 to 3.7 microg/g. CONCLUSION: Severe morphologic alterations were seen at the electron-microscopic level after application of MMC 0.2 mg/ml with a collagen shield and with a soft contact lens. They were mildest with lyophilisate and absent in the BSS controls. A new administration device is needed if trabeculectomy is to be performed successfully using MMC in human glaucomatous eyes.

Animals↗

Self-tonometry with the Ocuton S versus Goldmann tonometry.

BACKGROUND: The purpose of the study was to evaluate the acceptance and reproducibility of a new self-tonometer (Ocuton S) and to compare it with the Goldmann applanation tonometer. METHODS: The Ocuton S was studied in 20 healthy volunteers and 100 patients. After detailed explanation to each individual and a number of test measurements, we studied the reproducibility and accuracy of the Ocuton S in 20 healthy volunteers with and without topical anaesthesia. Acceptance was graded by means of visual analogue scales. Each volunteer had to measure his/her own IOP in three consecutive measurements. The data were compared with Goldmann tonometry at random times. One hundred patients were introduced to the Ocuton S. Either three consecutive self-measurements of IOP were performed and then compared with three consecutive measurements by Goldmann tonometry, or vice versa. This was done randomly. RESULTS: Forty-one of 100 patients were unable to perform three consecutive measurements with the Ocuton S after at least 15 min introduction time to the device (non-success). Fifty-nine of 100 patients were able to measure their IOP with the Ocuton S. The mean pressure value with the Ocuton S was 23.2+/-8.2 mmHg, compared with Goldmann 18. 4+/-5.7 mmHg. The difference of 5+/-5.7 mmHg was statistically significant (paired t-test p<0.01). The visual analogue scale scores of healthy volunteers (100 mm = maximal comfort, 0 mm = not acceptable), was 72+/-31 in anaesthetised eyes and 39+/-41 mm without anaesthesia. CONCLUSION: The Ocuton S seems to be an acceptable means for the majority of patients of measuring their IOP at home. Refinement of the accuracy of the device seems necessary.

Adult↗

Cellular photoablation to control postoperative fibrosis in a rabbit model of filtration surgery.

AIM: To evaluate the feasibility of cellular photoablation using fluorescence generated photoreaction products as a method to control postoperative fibrosis. METHODS: The fluorescent probe, 2',7'-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein, acetoxymethyl ester (BCECF-AM) is a cell membrane permeable compound rendered membrane impermeable and fluorescent upon cleavage by intracellular esterases. Rabbits (ChBB:CH; n=20) received a unilateral subconjunctival injection of BCECF-AM (40, 70, 80, or 100 microg) 30 minutes before surgery followed by intraoperative illumination with diffuse blue light (450-490 nm; 51.9 x 10(3) cd/m(2)) for 10 minutes. Controls received either the probe or illumination. Antifibrotic efficacy was established by clinical response and histological examination. Clinical response was assessed by comparing intraocular pressure (IOP) between the treated experimental eye and the fellow eye, which served as control. Success was defined by >20% difference in IOP. RESULTS: IOP was significantly decreased in all groups within 4 days postoperatively. In control groups IOP rose within 10 days to normal levels. This was similar in the group receiving 40 microg of BCECF-AM. In the other groups (subconjunctival injection of 70-100 microg BCECF-AM) IOP was significantly (p < 0.02) decreased for 2-3 weeks. Clinical and histological examination revealed no toxic damage to adjacent tissues. CONCLUSIONS: Cellular photoablation in contrast with chemotherapeutic agents acts on cells that have incorporated BCECF-AM and have been exposed to light at the appropriate wavelength. Though safety and reliability demand further studies this method might be an useful therapeutic approach to control postoperative fibrosis in humans undergoing filtration surgery.

Animals↗

Comparison of two fixed combinations of latanoprost and timolol in open-angle glaucoma.

OBJECTIVE: To compare the intraocular pressure (IOP)-reducing effect of the fixed combinations of timolol 0.5% and latanoprost 0.001% or 0.005% after 4 weeks' treatment. DESIGN: Following a 1-week run-in period on timolol 0.5% once daily, 139 patients were randomized to once-daily treatment with a fixed combination of timolol 0.5% and latanoprost 0.001% (comb. 10) or latanoprost 0.005% (comp. 50) or to the individual monotherapies. The IOP was measured at inclusion and at 8 a.m., noon and 4 p.m. on days 1, 7 and 28. RESULTS: Comb. 10, comb. 50, latanoprost and timolol reduced IOP by 3.7, 6.1, 4.9 and 2.1 mmHg, respectively, from a baseline mean diurnal IOP (+/- SEM) of 24.8 +/- 0.5, 24.1 +/- 0.4, 25.2 +/- 1.2 and 24.8 +/- 0.9 mmHg, respectively. The difference in IOP reduction was significant between comb. 50 and comb. 10 (P < 0.001), latanoprost (P = 0.046) and timolol (P < 0.001) in favor of comb. 50. There was also a significant difference between latanoprost and timolol (P = 0.007), in favor of latanoprost. All treatments were generally well tolerated. CONCLUSION: This study indicates that a fixed combination of latanoprost 0.005% and timolol 0.5% could be useful in the treatment of glaucoma.

Adult↗

Effect of mitomycin C on aqueous humor flow, flare and intraocular pressure in eyes with glaucoma 2 years after trabeculectomy.

BACKGROUND: The purpose of this study was to determine the intraocular pressure (IOP), aqueous humor flow, flare and ocular side effects in eyes with a history of hypotony after trabeculectomy with adjunctive mitomycin C (MMC). METHODS: Thirty-six eyes with primary or secondary open-angle glaucoma and IOP < or = 8 mmHg during the postoperative period were studied 745 +/- 315 days after surgery. MMC (0.2 or 0.5 mg/ml) was applied to the episclera with a cellular sponge. Flare was studied with the Kowa Laser Flare Meter 500. Aqueous humor flow was measured in the afternoon (Fluorotron Master II). IOP, visual fields and best corrected visual acuity were also examined. Twenty-two contralateral eyes without surgical intervention served as controls. RESULTS: The mean age of patients was 44.5 +/- 16.8 years. The mean IOP was significantly lower in the MMC group than in the control group: 9.6 +/- 6.4 mmHg vs 18.0 +/- 13.6 mmHg at 2 years (P < 0.001). Aqueous flow was significantly lower in subjects treated with MMC than in controls (P < 0.001). The flare values were significantly higher in the MMC-treated group, with a mean of 12.0 +/- 7.7 photon counts/ms, than in the control group, mean 7.9 +/- 4.6 photon counts/ms (P < 0.019). CONCLUSION: Our data suggest that MMC is a useful ocular hypotensive agent which seems to participate in a change in aqueous humor dynamics when applied topically as an aqueous solution.

Adolescent↗

Unilateral pigmentary degeneration of the retina associated with heterochromia iridis.

BACKGROUND: For the past 5 years, a 56-year-old patient has been displaying monocular progressive pigmentary changes in the left eye. Heterochromy of the left eye has been known since childhood. The other eye is clinically and functionally normal. The patient was adopted and he has no children. Therefore, we have no family history. METHODS: The patient was examined clinically and by means of electroretinography, electrooculography, perimetry, computer tomography, pulsatile ocular blood flow (POBF) measurement, serology and Doppler sonography. RESULTS: Electrophysiology displayed a considerable reduction of scotopic and photopic ERGs, a reduced dark-through, and a reduced light-rise in the left eye, whereas the fellow eye was normal. The visual field was limited to 5 deg around the fixation point, and a peripheral crescent-shaped arch encircled the temporal-inferior quadrant concomitant to the pigmentary changes. By computer tomography and Doppler sonography a vascular affection was excluded. The left eye displayed lower POBF values. All serological tests were found negative. CONCLUSION: The clinical picture and negative exclusion criteria indicate a unilateral retinitis pigmentosa. However, with regard to the literature an unequivocal diagnosis can only be made upon hereditary evidence.

Blood Flow Velocity↗

Dose uniformity of ophthalmic suspensions.

PURPOSE: To quantify the rate of redispersion of three commercially available ophthalmic preparations as well as the drug content of single drops during the course of emptying a full container of suspension eyedrops. SETTING: Department of Ophthalmology, University of Köln, and Department of Pharmaceutical Technology, University of Bonn, Germany. METHODS: In a computer-controlled test apparatus used to simulate the shaking and dropping behavior of humans under strictly reproducible conditions, we studied the rate of redispersion of three ophthalmic suspensions: 50 mg indomethacin, 50 mg prednisolone-21-acetate, and 50 mg dexamethasone in 5 mL of aqueous fluid. The degree of shaking intensity essential for the redispersion of the ophthalmic suspensions was quantified in healthy persons and patients by an acceleration sensor. RESULTS: The mean dose delivered and the coefficient of variation of prednisolone were satisfactory. However, only 25% of the dexamethasone was available for administration; the rest remained in the bottle as a cake of sediment. Also, the variability of the drug content between drops was unacceptably high. The mean dose of indomethacin was adequate, but the between-drop variability was excessive. CONCLUSION: The dose uniformity of suspension eyedrops depends on their homogeneity immediately before administration. Among the formulation factors studied, particle size appears to be the most important. The various redispersion rates of the three drugs underline their clinical profile.

Administration, Topical↗

Ocular concentrations of mitomycin C using different delivery devices.

Hypotony and its sequelae are a frequent complication of trabeculectomies performed with mitomycin C (MMC), possibly related to intraocular toxicity of the substance. In an animal model with rabbits, we used different devices for the application of MMC and measured extra- and intraocular concentrations by HPLC. In addition, the concentrations of MMC remaining in the devices were determined. The devices were (1) a regular surgical sponge, (2) a scleral shield, (3) a presoaked soft contact lens, (4) a soft contact lens with MMC application, and (5) subconjunctival injection. Ocular concentrations of MMC were similar within the first 4 groups and were highest in the last. The measurements suggest that MMC penetrates intraocularly regardless of the device used. The variability of remaining MMC concentrations in the devices was lowest in the soft contact lenses suggesting an improved delivery system compared to the usually used surgical sponges.

Administration, Topical↗

Efficacy of argon laser trabeculoplasty: 3-year preliminary results of a prospective placebo-controlled study.

BACKGROUND: It was the purpose of this study to evaluate the efficacy of argon laser trabeculoplasty (ALT) in controlling intraocular pressure (IOP) and avoiding surgical intervention. We also investigated whether topically applied diclofenac sodium eye drops had an influence on the success rate of ALT compared with placebo eye drops. METHODS: The indication for ALT was progressive glaucoma uncontrolled by maximal tolerated medical therapy. Thirty-nine of 41 patients were available for follow-up after 1122 +/- 239 days. RESULTS: Twenty-one of 39 eyes failed during the first 3 years of follow-up for one or more reasons: 11 eyes required additional laser treatment and/or filtration surgery because of progressive visual field loss or unacceptably high IOP, 9 eyes failed to have a final IOP > or = 21 mmHg, and 7 eyes failed because of an increase in the number of the medications. This yields a success rate for ALT of 46% for 3-year follow-up. There was no significant difference between diclofenac sodium- and placebo-treated eyes concerning the success rate after 3 years (P > 0.05). CONCLUSION: We conclude that the use of ALT for the treatment of glaucoma is best reserved for cases in which medical avenues of treatment have been exhausted.

Adult↗

The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humour protein concentration in glaucoma patients. A randomized, double-masked comparison with timolol 0.5%.

BACKGROUND: Latanoprost is a PGF2 alpha analogue which reduces the intraocular pressure (IOP) by increasing the uveoscleral outflow. The objective of this study was to investigate the effect of two different regimens of latanoprost on the diurnal IOP and also the effect of latanoprost on the blood-aqueous barrier measured with a laser flare cell meter (Kowa FM-500). Moreover, the safety aspects of the two regimens regarding hyperemia were studied. METHODS: A double-masked, randomized study was performed in 30 patients (9 males, 21 females; mean age 61.9 years) with primary open-angle glaucoma or pseudoexfoliation glaucoma. Twenty patients were treated with latanoprost 0.0015% twice daily or 0.005% once daily for 3 weeks in a cross-over design. Ten patients received timolol 0.5% twice daily as control. RESULTS: Latanoprost 0.005% once daily reduced IOP (+/- SEM) more effectively than latanoprost 0.0015% twice daily (9.8 +/- 0.9 mm Hg and 6.7 +/- 0.9 mm Hg, respectively). There was a statistically significant increase in the aqueous humour protein concentration within the timolol group (P = 0.004), but not within the latanoprost group (P = 0.97). There was no statistically significant difference in the change in aqueous humour protein concentration from baseline between latanoprost and timolol groups (P = 0.08). No statistically significant difference in conjunctival hyperemia between the two latanoprost regimens was found (P = 0.37). CONCLUSION: Latanoprost 0.005% once daily reduced IOP more effectively than latanoprost 0.0015% twice daily (P < 0.001). Latanoprost had no statistically or clinically significant effect on the blood-aqueous barrier. There was no difference in hyperemia between the two regimens. Both concentrations of latanoprost reduced IOP at least as well as timolol 0.5% eye drops.

Adrenergic beta-Antagonists↗

[Laser flare measurement with 3 different nonsteroidal anti-inflammatory drugs after phacoemulsification with posterior chamber lens implantation].

In a prospective, randomised, double-masked, parallel-group study we compared the antiinflammatory effect of diclofenac sodium 0.1%, flurbiprofen 0.03%, and indomethacin 1.0% ophthalmic suspension in 99 patients undergoing phacoemulsification and posterior chamber lens implantation. The reduction in anterior chamber flare from day 1, as measured with the laser flare-meter (FM-500, KOWA) on day 4-5 postoperatively was significantly greater in the diclofenac group than with flurbiprofen (p = 0.022). Patients treated with diclofenac had significantly less burning and stinging than patients on flurbiprofen and indomethacin on postoperative days 4-5 (p < 0.0001) and 12-14 (p = 0.001). Diclofenac sodium appears to be more potent than flurbiprofen in controlling intraocular inflammation after cataract surgery, while having better local tolerance than flurbiprofen or indomethacin.

Adult↗

Clinical dose-regimen studies with latanoprost, a new ocular hypotensive PGF2 alpha analogue.

This review summarizes recent short-term clinical studies evaluating the ocular hypotensive efficacy of different dose-regimens of latanoprost. When tested in ocular hypertensive and glaucoma patients concomitantly treated with timolol, 0.006% latanoprost given only in the evening, was found to be more effective than the same concentration given in the morning and evening. In patients with open angle, pseudoexfoliation and normal tension glaucoma not receiving other treatment, once-daily 0.005% latanoprost monotherapy was more effective than twice-daily 0.0015% latanoprost treatment. No significant differences were found in conjunctival hyperemia, sensory irritation or blood-aqueous barrier permeability between these two treatment regimens. Although the ocular hypotensive efficacy of once-daily application of the lower concentration (0.0015%) latanoprost was not investigated, we would conclude, based on the studies reviewed here, that at a concentration of 0.005%, once-a-day dosing of latanoprost is highly effective in significantly reducing intraocular pressure, causing only minimal, clinically acceptable short-term ocular side effects.

Administration, Topical↗

Do standard procedures in squint surgery influence the blood-aqueous barrier?

BACKGROUND AND OBJECTIVE: Surgery on the rectus muscles may interfere with anterior segment perfusion. This study investigates the influence of combined rectus muscle surgery on the blood-aqueous barrier in children. Namely, the influences of tucking and resection procedures were compared. PATIENTS AND METHODS: Laser flare measurements for tyndallometry were performed preoperatively and postoperatively in 25 children. Fifteen of the children had undergone a combination of a rectus recession and tucking; 10 had undergone a combined recession-resection procedure. RESULTS: The mean preoperative flare value was 4.1 photon counts/ms versus 3.7 photon counts/ms postoperatively in the eyes that had undergone surgery. Statistical evaluation showed that the postoperative changes were insignificant. No significant difference was found between the two surgical techniques (tucking vs resection) regarding the preoperative versus postoperative flare value change (level of statistical significance .05). CONCLUSION: Combined squint surgery, either recession-tucking or recession-resection, was not shown to influence the blood-aqueous barrier.

Anterior Eye Segment↗

Histopathology of episcleral fibrosis after trabeculectomy with and without mitomycin C.

BACKGROUND: The aim of the study was to investigate the histopathologic features of scar tissue which have proliferated at the site of trabeculectomy of surgical failures after procedures with and without the use of the antimetabolite mitomycin C (MMC). METHODS: We obtained seven surgical specimens after trabeculectomy without MMC and five specimens after trabeculectomy with MMC, which were compared with 23 controls. Sections were stained with hematoxylin and eosin, Verhoeff-van Gieson, Grocott methenamine silver, and alcian blue. An immunohistochemical stain was performed for alpha-smooth muscle actin. RESULTS: Specimens from eyes operated without MMC showed dense scar tissue with many fibroblasts, much ground substance, parallel-oriented collagen fibers, and contractile intracellular proteins within the fibroblasts. Specimens from eyes operated with MMC consisted of tissue with only few fibroblasts which did not exhibit contractile proteins. Collagen fibers were arranged randomly with less ground substance. CONCLUSION: Even after 1-10 months, the scar tissue was distinctly different in the two groups. These results suggest that the use of MMC has long-term effects in vivo. Surgical failures related to scar formation are possible and not reduced to zero.

Actins↗

Effect of 3.0 mm tunnel and 6.0 mm corneoscleral incisions on the blood-aqueous barrier.

PURPOSE: To study of the effect of silicone intraocular lens (IOL) implantation using a 3.0 mm tunnel incision with that of implantation though a 6.0 mm corneoscleral incision after phacoemulsification in human eyes. SETTING: Department of Ophthalmology, University of Köln, Germany. METHODS: In a prospective, randomized clinical study, 50 patients with senile cataract had phacoemulsification and IOL implantation through a 3.0 mm tunnel or a 6.0 mm corneoscleral incision. To assess blood-aqueous barrier (BAB) disruption, preoperative and postoperative sodium fluorescein concentrations in the anterior chamber were measured with the Fluorotron Master II. Diclofenac sodium 0.1% was applied to the operative eyes five times a day for 5 days. The contralateral eyes served as controls. RESULTS: There was no significant between-group difference in sodium fluorescein concentrations in the 5 days after surgery. CONCLUSION: The findings underline our clinical impression that BAB disruption 5 days after surgery does not differ significantly with the type and length of scleral incision used for IOL implantation.

Analysis of Variance↗

Efficacy and tolerance of diclofenac sodium 0.1%, flurbiprofen 0.03%, and indomethacin 1.0% in controlling postoperative inflammation.

PURPOSE: To compare the anti-inflammatory effect of diclofenac sodium 0.1% ophthalmic solution, flurbiprofen 0.03% ophthalmic solution, and indomethacin 1.0%. SETTING: Department of Ophthalmology, University of Köln, and Bundesknappschaftskrankenhaus, Sulzbach, Germany. METHODS: One hundred seventeen patients enrolled in this prospective, randomized, double-masked, and parallel-group study had phacoemulsification and intraocular lens implantation and received one of the three solutions. Preoperatively at day 1 and postoperatively at day 4 or 5 and day 12, 13, or 14, they were examined by slitlamp, applanation tonometry, and laser flare meter. RESULTS: Anterior chamber flare reduction from baseline was significantly greater in the diclofenac group than in the flurbiprofen group (P = .022). Patients in the diclofenac group had significantly less burning and stinging than those in the flurbiprofen and indomethacin groups at postoperative days 4-5 and 12-14 (P = .001). CONCLUSION: Diclofenac sodium appeared to be more potent than flurbiprofen in controlling intraocular inflammation after cataract surgery and appeared to be locally tolerated better than flurbiprofen and indomethacin.

Administration, Topical↗